CSIMarket Company Name, Ticker, Suppliers, else..
 
Black Diamond Therapeutics Inc   (BDTX)
Other Ticker:  
 
 
Price: $6.1900 $0.34 5.812%
Day's High: $6.2 Week Perf: 9.36 %
Day's Low: $ 5.86 30 Day Perf: 23.8 %
Volume (M): 420 52 Wk High: $ 7.66
Volume (M$): $ 2,602 52 Wk Avg: $4.24
Open: $5.86 52 Wk Low: $1.62



 Market Capitalization (Millions $) 341
 Shares Outstanding (Millions) 55
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for cancer treatment. They utilize their proprietary platform called Mutation-Allostery-Pharmacology (MAP) to identify and target specific genetic mutations that drive cancer growth. By addressing these mutations, Black Diamond aims to create novel and effective therapies that improve patient outcomes. They are dedicated to advancing precision medicine and tackling the most challenging oncology indications.


   Company Address: One Main Street, 14th Floor Cambridge 2142 MA
   Company Phone Number: 252-0848   Stock Exchange / Ticker: NASDAQ BDTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

AbstractRecurrent glioblastoma multiforme (GBM), a highly aggressive m...

Published Sat, Jun 1 2024 2:00 PM UTC

'A Promising Step Forward in Glioblastoma Treatment: BDTX-1535 Shows Encouraging Clinical Data''Abstract'Recurrent glioblastoma multiforme (GBM), a highly aggressive malignant brain tumor, remains one of the most challenging cancers to treat due to its resistance to conventional therapies and poor prognosis. In the ongoing pursuit of novel therapeutic strategies, Black Diamo...
Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc Shows Positive Progress with Operating Shortfall Improvement in Q1 2024 Earnings Season

Black Diamond Therapeutics Inc Faces Uphill Battle Despite Positive Financial Results
Black Diamond Therapeutics Inc, a clinical-stage oncology company, recently reported positive financial results for the first quarter of 2024. However, a deeper analysis reveals that the company still faces significant challenges and may not be a wise investment choice for shareholders.
Firstly, let's address the operating shortfall of $-20.246 million for the first quarter of 2024. While it may seem like an improvement from the previous year's shortfall of $-21.561 million, it is crucial to note that there were no easier benchmarks to measure against. This positive surprise could be misleading, as it merely signifies that the company's performance was slightly less disappointing than the previous year. Analysts' confidence in the company should be taken with caution, as there are no clear signs of robust growth or financial stability.
Clinical Study

Black Diamond Therapeutics to Illuminate ASCO Annual Meeting with Groundbreaking oncology presentations

Published Wed, Apr 24 2024 8:05 PM UTC

Black Diamond Therapeutics, Inc., a prominent clinical-stage oncology company committed to revolutionizing treatment paradigms, has recently revealed that it will play a key part at the forthcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Set to take place from May 31 to June 4 in Chicago, Illinois, the reputed event will witness two crucial poster p...
Clinical Study

Black Diamond Therapeutics Strengthens EGFR Mutation Landscape in NSCLC - A Fresh Hope for Patients with Novel BDTX-1535.

Published Sun, Apr 7 2024 10:00 PM UTC

The company presented robust data underlining that 20-30% of all patients diagnosed with EGFR mutation NSCLC, which is the most common type of lung cancer, are confronting non-classical mutations. This current scientific evidence emphasizes the imperative necessity for better EGFR mutation testing procedures and therapies for lung cancer patients worldwide, direct to this pa...
Black Diamond Therapeutics Inc

Strategic Cost Management Leads to Improved Financial Performance at Black Diamond Therapeutics Inc

Interpreting the financial results of Black Diamond Therapeutics Inc, a clinical-stage oncology company, it is evident that the company has made significant progress in fiscal year 2023. The company reported an operating loss of $-20.855 million for the October to December 31, 2023 span, which indicates a more cost-effective approach compared to the previous fiscal year.
In the fiscal period ending December 31, 2022, Black Diamond Therapeutics Inc had reported an operating loss of $-21.852 million. Therefore, it is encouraging to see a decrease in losses from the prior year. The deficit in the December 31, 2023 span was $-19.408 million, compared to $-21.078 million in the fourth quarter of 2022.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com